AMPHAmphastar Pharmaceuticals, Inc.
$25.83+0.00% 1Y
$25.83
$16.8752 weeks$29.40
The financials
Amphastar Pharmaceuticals, Inc. by the numbers
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $184M in Q2 2026 (quarter ended Jun 30, 2026), up 5.4% from the same quarter a year earlier. That came with a gross margin of 51% and net income of $30M (17% of revenue). For the full year FY2025, revenue was $720M (−1.7% year on year) and net income $98M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $184M | $174M | +5.4% |
| Gross profit | $93M | $86M | +8.1% |
| Operating income | $40M | $42M | −5.8% |
| Net income | $30M | $31M | −2.2% |
| Diluted EPS | $0.67 | $0.64 | +4.7% |
Drug Manufacturers, Specialty & Generic
Ranks #4 of 41 by RyuScore